Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. (Q54541283)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. |
scientific article |
Statements
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors (English)
Dirk Strumberg
Beate Schultheis
Ulrich Traugott
Christiane Vank
Ansgar Santel
Oliver Keil
Klaus Giese
Jörg Kaufmann
Joachim Drevs
1 January 2012